Drug-resistant Trials

Trials for Gleevec, Sutent, Stivarga resistant GIST

The trials listed below are for Gleevec-resistant GIST (in most cases, Sutent-resistant as well). Click on the hyperlinks for more details about each trial. You will also have the opportunity to access trial site data later. Trials are sorted so that trials that are only for GIST appear first. Trials are also sorted so that trials in later phases sort higher on the list. Phase I trials are included in this listing. Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov. The drug name listed will be the most advanced available; i.e., brand name first or generic name and if neither of those are available, IND.

20 trials found

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
Phase:  3
Category:   KIT/PDGFRA inhibitor + D842V inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Dana Farber Cancer Institute Boston MA USA
Memorial Sloan-Kettering Cancer Center New York NY USA
Ohio State University Comprehensive Cancer Center Columbus OH USA
Fox Chase Cancer Center Philadelphia PA USA
MD Anderson Cancer Center Houston TX USA
Centre Léon Bérard Lyon Rhone France
Asan Medical center Seoul Songpa-gu Republic of Korea
Mayo Clinic Cancer Center Phoenix AZ USA
Mayo Clinic, Jacksonville Jacksonville FL USA
University of Michigan Ann Arbor MI USA
Institut Gustave Roussy Villejuif Val de Narne France
Institut Bergonie Bordeaux Gironde France
Royal Marsden Hospital - Chelsea London UK
Lund University Hospital Lund Sweden
Monash Health Clayton Australia
H. Lee Moffit Cancer Center Tampa FL USA
Mayo Clinic, Rochester Rochester MN USA
University of Pittsburgh Cancer Institute Pittsburgh PA USA
Tennessee Oncology Nashville TN USA
Seoul National University Hospital Seoul Republic of Korea
Severance Hospital, Yonsei University Health System Seoul Republic of Korea
Summit Cancer Centers - Spokane Spokane WA USA
University Health Network Toronto ON Canada
University of Colorado Aurora CO USA
Robert Lurie Comp. Cancer Center Northwestern University Hospital Chicago IL USA
Washington University School of Medicine St. Louis MO USA
Duke Cancer Institute Durham NC USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
Huntsman Cancer Institute Salt Lake City UT USA
Fred Hutchinson Cancer Research Center Seattle WA USA
Medical College of Wisconsin Milwaukee WI USA
Canberra Hospital Garran Australian Capital Territory Australia
Institut Jules Bordet Brussels Belgium
Leuven Cancer Institute, Catholic University Leuven Leuven Belgium
Cross Cancer Institute Edmonton Alberta Canada
Centre Oscar Lambret - Bordeaux Lille France
Institut Paoli Calmette Marseilles France
Hospital de La Timone Marseille France
Centre Rene Gauducheau Nantes France
Helios Klinikum Bad Saarow Bad Saarow Germany
Helios Klinikum Berlin-Buch Berlin Germany
Universitatsklinikum Essen, West Germany Cancer Center Essen Germany
Policlinico S. Orsola-Malpighi Bologna Italy
Istituto Nazionale Dei Tumori Milan Italy
Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone Palermo Italy
Universita Campus Bio-Medico di Roma Rome Italy
Samsung Medical Center Seoul Republic of Korea
Marie Sklodowska-Curie Memorial Cancer Center Warsaw Poland
National Cancer Center Singapore Singapore
Hospital Santa Creu i Sant Pau Barcelona Spain
CO L'Hospitalet - Hospital Duran i Reynals Barcelona Spain
Hospital Vall d'Hebron Barcelona Spain
University Hospital La Paz Madrid Spain
Hospital Virgen del Rocio Sevilla Spain
Beatson West of Scotland Cancer Centre Glasgow UK
The Christie NHS Foundation Trust Manchester UK
Sheffield Teaching Hospital Sheffield UK
Flinders Medical Centre Bedford Park South Australia Australia
Allgemeines Krankenhaus Vienna Austria
Pécsi Tudományegyetem, Orvostudományi és észségtudományi Centrum, Onkoterápiás Intéze Pécs Hungary
UCLA Hematology/Oncology Santa Monica CA USA
Washington Hospital Center - Oncology/Hematology Washington DC USA
Northside Hospital Atlanta GA USA
Texas Oncology Waco TX USA
Jewish General Hospital Montreal Quebec Canada
Fackultni Nemocnice v Motole Prague Czechia
Medizinische Fakultat Carl Gustav Carus Dresden Germany
Universitatsklinikum Frankfurt Frankfurt Germany
Studienzentrale GbR Lubecker Onkologische Schwerpunktpraxis Lubeck Germany
Ruoercht-Karis-Universitaet Heidelberg Mannheim Germany
Fovarosi Onkormanyzat Szenf Laszio Korhaz Budapest Hungary
Magyar Honvedseg Egeszsugugyi Kozpont Onkologiai Osztaly Budapest Hungary
Medical Oncology University Debrecen Debrecen Hungary
AOUC Azienda Ospedaliero - Universitaria Careggi Firenze Italy
Instituto Europeo di Oncologia Milano Italy
Ajou University Hospital Suwon Republic of Korea
Samodzieiny Publiczny Zaklad Opieki Zdrowotnej Olsztyn Poland
Dolnoslaskie Centrum Onkologii we Wrocawiu Wroclaw Poland
hospital Universitario Miguel Servet Zaragosa Spain
Guy's Hospital London UK
Texas Oncology - Baylor Charles A Sammons Cancer Center Dallas TX USA
 


Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
Phase:  3
Category:   D842V
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Sarcoma Oncology Center Santa Monica CA USA
Knight Cancer Institute at Oregon Health Sciences University (OHSU) Portland OR USA
Fox Chase Cancer Center Philadelphia PA USA
MD Anderson Cancer Center Houston TX USA
Duke Cancer Institute Durham NC USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Institut Bergonie Bordeaux Gironde France
Centre Oscar Lambret - Lille Lille Nord France
Centre Léon Bérard Lyon Rhone France
Hospital de La Timone Marseille France
Centre Val d'Aurele Montpellier France
CHU de Reimes - Hôpital Pontchaillou Reimes France
Institut Gustave Roussy Villejuif Val de Narne France
Helios Klinikum Berlin-Buch Berlin Germany
Universistatsklinikum Mannheim Mannheim Germany
Klinikum der Universitaet Muenchen-Grosshadem Campus Munich Germany
Istituto Nazionale Dei Tumori Milan Italy
Norwegian Radium Hospital Oslo Norway
Centrum Onkologii - Instytut Im. Sklodowskiej-Curie w Warszawie Warsaw Poland
Hospital Vall d'Hebron Barcelona Spain
Hospital Universitario Puerta de Hierro de Majadahonda Madrid Spain
Cambridge University Hospitals Cambridge UK
Royal Marsden Hospital - Chelsea London UK
Policlinico S. Orsola-Malpighi Bologna Italy
Institut Regina Elena / IFO Rome Italy
Candiolo Cancer Institute - FPO, IRCCS Turin Italy
Hospital Virgen del Rocio Sevilla Spain
Fundación Instituto Valenciano de Oncología Valencia Spain
Sheffield Teaching Hospital Sheffield UK
 


A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)
Phase:  3
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Georgia Cancer Specialists - Sandy Springs Sandy Springs GA USA
Mayo Clinic, Jacksonville Jacksonville FL USA
Mayo Clinic, Rochester Rochester MN USA
Fox Chase Cancer Center Philadelphia PA USA
Emily Couric Clinical Cancer Center Charlottesville VA USA
University of Toledo Toledo OH USA
Texas Oncology - Baylor Charles A Sammons Cancer Center Dallas TX USA
University of Colorado Aurora CO USA
Rocky Mountain Cancer Centers Denver CO USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
University of Iowa Hospitals and Clinics Iowa City IA USA
Dana Farber Cancer Institute Boston MA USA
Washington University School of Medicine St. Louis MO USA
Arthur G. James Cancer Hospital Columbus OH USA
Oklahoma University Cancer Institute Oklahoma City OK USA
Alfred University Melbourne Australia
Princess Margaret Hospital Toronto ON Canada
National Cancer Center Singapore Singapore
Miami Cancer Institute at Baptist Health Miami FL USA
Oregon Health & Science University Portland OR USA
Emory Winship Cancer Institute Atlanta GA USA
University of Chicago Chicago IL USA
Indiana University Simon Cancer Center Indianapolis IN USA
Montefiore Bronx NY USA
Memorial Sloan-Kettering Cancer Center New York NY USA
Duke Cancer Institute Durham NC USA
Vanderbilt-Ingram Cancer Center Nashville TN USA
Virginia Commonwealth University Massey Cancer Center Richmond VA USA
Medical College of Wisconsin Milwaukee WI USA
Prince of Wales Hospital Randwick New South Wales Australia
Princess Alexandra Hospital Woolloongabba Queensland Australia
Ottawa Regional Cancer Center University of Ottawa Ottawa Ontario Canada
Juravinski Cancer Center Hamilton Ontario Canada
Istituto Nazionale Dei Tumori Milan Italy
Oslo University Hospital Oslo Norway
Centrum Onkologii - Instytut Im. Sklodowskiej-Curie w Warszawie Warsaw Poland
Hospital Santa Creu i Sant Pau Barcelona Spain
Hospital Universitari Vall d'Hebrón Barcelona Spain
Royal Marsden Hospital - Chelsea London UK
Border Medical Oncology Research Unit Albury NSW Australia
The Monter Cancer Center Lake Success NY USA
Norton Cancer Institute, Audobon Hospital Campus Louisville KY USA
Smilow Cancer Hospital at Yale New Haven CT USA
UCLA Hematology Oncology Center - Main Site Los Angeles CA USA
University of California San Diego Medical Center La Jolla CA USA
Ashford Cancer Centre Research Kurrulta Park South Australia Australia
Chang Gung Memorial Hospital Linkou Taoyuan County Taiwan
 


A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
Phase:  2
Category:   HSP90 inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
National Health Research Institute Taiwan
 


Ph II CABOGIST in GIST
Phase:  2
Category:   KIT/PDGFRA inhibitor + MET/VEGF inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Universitair Ziekenhuis Gasthuisberg Leuven Belgium
Institut Bergonie Bordeaux Gironde France
Centre Léon Bérard Lyon Rhone France
Institut Gustave Roussy Villejuif Val de Narne France
University College Hospital London UK
Christie Hospital NHS Trust Manchester Lancashire UK
Royal Marsden Hospital - Chelsea London UK
University Hospital Motol Prague Czechia
UniversitaetsMedizin Mannheim Mannheim Germany
Military Hospital - State Health Centre Budapest Hungary
Clatterbridge Centre for Oncology NHS Trust Bebington UK
 


A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs
Phase:  2
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Asan Medical center Seoul Songpa-gu Republic of Korea
 


MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Phase:  2
Category:   KIT/PDGFRA inhibitor + MEK inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Memorial Sloan-Kettering Cancer Center New York NY USA
 


Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
Phase:  2
Category:   PD-1 inhibitor + CTLA-4 inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
UCLA's Jonsson Comprehensive Cancer Center Los Angeles CA USA
 


POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST (POETIG)
Phase:  2
Category:   KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI)
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Universitatsklinikum Essen, West Germany Cancer Center Essen Germany
 


Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor
Phase:  2
Category:   SDH-directed
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Moores Cancer Center/UCSD Medical center La Jolla CA USA
 


Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC)
Phase:  2
Category:   Immunotherapeutic
Conditions:  Sarcoma

Site
City
State
Country
Institut Bergonie Bordeaux Gironde France
Centre Oscar Lambret - Lille Lille Nord France
Centre Léon Bérard Lyon Rhone France
Institut Paoli-Calmette Marseille Bouches du Rhone France
St. Herblain Nantes Loire Atlantique France
Institut Claudius Regaud Toulouse France
Institut Gustave Roussy Villejuif Val de Narne France
Instituit Curie Paris France
 


Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations (AcSé)
Phase:  2
Category:   BRAF inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
Hopital Saint-Joseph Service Oncologie Paris France
 


A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Phase:  1
Category:   KIT/PDGFRA inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
MD Anderson Cancer Center Houston TX USA
Princess Margaret Hospital Toronto ON Canada
Dana Farber Cancer Institute Boston MA USA
HonorHealth Virginia Piper Cancer Center Scottsdale AZ USA
Stanford Cancer Center Palo Alto CA USA
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Oregon Health & Science University Portland OR USA
Memorial Sloan-Kettering Cancer Center New York NY USA
Fox Chase Cancer Center Philadelphia PA USA
Huntsman Cancer Institute Salt Lake City UT USA
Royal Marsden Hospital - Chelsea London UK
Mayo Clinic, Jacksonville Jacksonville FL USA
Leiden University Leiden Netherlands
 


Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Phase:  1
Category:   Immune stimulate
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Ohio State University Comprehensive Cancer Center Columbus OH USA
 


Ipilimumab and Imatinib Mesylate in Advanced Cancer
Phase:  1
Category:   KIT/PDGFRA inhibitor + CTLA4 inhibitor
Conditions:  Advanced Cancer

Site
City
State
Country
MD Anderson Cancer Center Houston TX USA
 


A Study of XmAb®18087 in Subjects With NET and GIST
Phase:  1
Category:   SSTR2 + CD3 inhibitor
Conditions:  Gastrointestinal Stromal Tumor

Site
City
State
Country
Emory Winship Cancer Institute Atlanta GA USA
City of Hope Duarte CA USA
MD Anderson Cancer Center Houston TX USA
 


Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
Phase:  1/2
Category:   SDH-directed
Conditions:  Solid Tumors

Site
City
State
Country
South Texas Accelerated Research Therapeutics (START) San Antonio TX USA
 


Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors
Phase:  2
Category:   TRK Inhibitor
Conditions:  Sarcoma

Site
City
State
Country
Stanford University Medical Center Palo Alto CA USA
Memorial Sloan-Kettering Cancer Center New York NY USA
Fox Chase Cancer Center Philadelphia PA USA
Vanderbilt-Ingram Cancer Center Nashville TN USA
MD Anderson Cancer Center Houston TX USA
Samsung Medical Center Seoul Republic of Korea
Inova Health System Fairfax VA USA
Ronald Reagan UCLA Medical Center Los Angeles CA USA
Massachusetts General Hospital Boston MA USA
Dana Farber Cancer Institute Boston MA USA
Dartmouth-Hitchcock Medical Center Lebanon NH USA
Wake Forrest Winston-Salem NC USA
Cleveland Clinic Taussig Cancer Center Cleveland OH USA
University of Washington - Seattle Cancer Care Alliance Seattle WA USA
National Cancer Center Singapore Singapore
Hospital Vall d'Hebron Barcelona Spain
Medstar Hospital Washington Washington DC USA
Memorial Hospital Pembroke Pines FL USA
Thomas Jefferson University Philadelphia PA USA
West Virginia University Morgantown WV USA
Copenhagen University Hospital Copenhagen Denmark
St Vincent's University Hospital Dublin Ireland
Severance Hospital, Yonsei University Health System Seoul Republic of Korea
John Theurer Cancer Center at Hackensack Hackensack NJ USA
Avera Cancer Institute Sioux Falls SD USA
Fundacion Jimenez Diaz Madrid Spain
Institut Bergonie Bordeaux Gironde France
Seoul National University Hospital Seoul Republic of Korea
University College Hospital London UK
Roswell Park Cancer Institute Buffalo NY USA
University of Chicago Chicago IL USA
Barts Health NHS Trust Royal London London UK
University Hospital Southampton Southampton UK
Centro Integral Oncologico Clara Campal Madrid Spain
Instituto Purtugues de Oncologia do Porto Francisco Gentil Porto Portugal
University of North Carolina (UNC) Chapel Hill NC USA
 


Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Phase:  1
Category:   PD-1 + LAG-3 Inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
University of Chicago Chicago IL USA
Johns Hopkins Sidney Kimmel Comp Cancer Center Baltimore MD USA
Dana Farber Cancer Institute Boston MA USA
Memorial Sloan-Kettering Cancer Center New York NY USA
Providence Portland Medical Center Portland OR USA
Karmanos Cancer Institute Detroit MI USA
Helsinki University Central Hospital Helsinki Finland
Institut Claudius Regaud Toulouse France
Site name unknown Napoli 80131 Napoli Italy
Hospital Vall d'Hebron Barcelona Spain
Clinica universitaria Navarra Plamplona Spain
Centre Hospitaleir Universitaire Vaudois Lausanne Switzerland
Seattle Cancer Care Alliance Seattle WA USA
Medizinische Universtaet Wien Vienna Austria
 


A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors
Phase:  1
Category:   HIF-2a Inhibitor
Conditions:  Solid Tumors

Site
City
State
Country
University of Miami, Sylvester Comprehensive Cancer Center Miami FL USA
Dana Farber Cancer Institute Boston MA USA
Beth Israel Deaconess Medical Center Boston MA USA
Massachusetts General Hospital Boston MA USA
Wake Forrest Winston-Salem NC USA
Tennessee Oncology Nashville TN USA
South Texas Accelerated Research Therapeutics (START) San Antonio TX USA
 


20 trials found